NEKTAR AND BAXTER COLLABORATE TO DEVELOP NOVEL LONGER-ACTING FORMS OF BLOOD CLOTTING FACTORS

Nektar Therapeutics today announced an agreement with subsidiaries of Baxter International Inc. to develop PEGylated therapeutic forms of blood clotting proteins for patients with hemophilia, in order to reduce the frequency of injections required to treat blood clotting disorders such as hemophilia A. "This agreement allows Nektar to capitalize on the internal work we have done on PEGylated proteins and provides Baxter with a differentiated product opportunity to maintain their market leadership," said Ajit Gill, Nektar President and Chief Executive Officer.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050929005261&newsLang=en)